EC Microbiology

Introduction: The potential threat of new coronavirus outbreak (COVID-19, SARS-CoV-2) maintains worldwide. The therapeutic strategies (drug targeting, selection and combination) to COVID-19 infectious need new biological theory and pharmaceutical insights. To cope with these therapeutic progress, long COVID and clinical treatment selections are key avenues for cost-effective consideration and therapeutic breakthroughs.

Methods: To speed up drug development and clinical therapeutics against COVID-19, advanced diagnosis, different therapeutic modality, drug selection and combination should be systematically investigated. Targeting infectious and therapeutic variability, biomedical mechanism, novel evaluative architecture and drug development pipelines should be integrated.

Results: By the invention of novel evaluative modalities, viral infectious biology, pathophysiology properties and computational aids/designs can be gradually understood. Facilitating comparison between drug develop and clinical application against different facet of viral-induced infections and social threats should be effectively established. Based on biological and pharmaceutical aspects of medical progress, communication and dialogues between doctors and patients for drug selection should be a future trend. COVID-19 infection has been regarded as a disease of past. But this world had a great shortage of information and knowledge about viral progress diversity in different people. Considering the high infectivity of humans, life expectancy for global population decreased in the past. There is a high necessity for future at several regions and countries.

Conclusion: The intensified COVID-19 study may boost viral diagnostic and treatment worldwide.

 Keywords: COVID-19; Drug Evaluation; Herbal Medicine; Drug Selection, Anti-Viral Drug Development; Computational Drug Design

1. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China”. New England Journal of Medicine 8 (2020): 727-733.
2. Ciotti M., et al. “COVID-19 outbreak: An overview”. Chemotherapy 5-6 (2019): 215-223.
3. Lu DY., et al. “Coronavirus (COVID-19), origin, infectivity, epidemics, therapeutics and global impacts”. EC Pharmacology and Toxicology3 (2021): 100-107.
4. Barupal T., et al. “COVID-19: morphology, characteristics, symptoms, prevention, clinical diagnosis and current scenario”. Coronavirus1 (2020): 82-89.
5. Lu DY and Lu TR. “COVID-19 study, public health and biomedical bases”. Current Drug Therapy4 (2024): 367-375.
6. Perlman S and Peiris M. “Coronavirus research: knowledge gaps and research priorities”. Nature Reviews Microbiology 3 (2023): 125-126.
7. Kim YK. “RNA therapy. Rich history, various applications of unlimited future prospects”. Experimental and Molecular Medicine4 (2022): 455-465.
8. Katta M., et al. “A preliminary review on novel coronavirus diseases: COVID-19”. Coronavirus1 (2020): 90-97.
9. Lu DY and Lu TR. “Covid-19 study, diagnostic and therapeutic transition”. Recent Advances in Anti-Infective Drug Discovery 1 (2024): 21-35.
10. Naqvi IA and Tazvi SNZ. “The comprehensive appraisal of COVID-19: its clinical panorama from virology till management and beyond”. Coronavirus1 (2020): 57-72.
11. Chandel SRV., et al. “Understanding the molecular mechanisms of SARS-CoV2 infection and propagation in human to discover potential preventive and therapeutic approach”. Coronavirus1 (2020): 73-81.
12. Hetez PJ. “SARS-Cov-2 variants after a second chance to fix vaccine inequities”. Nature Reviews Microbiology 21 (2023): 127-128.
13. Mitra M. “Coronavirus vaccination advancement”. EC Emergency Medicine and Critical Care7 (2021): 89-96.
14. Liu T., et al. “Design strategies for and stability of mRNA-lipid nanoparticle COVID-19 vaccines”. Polymers19 (2022): 4195.
15. Rahman MM., et al. “A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges”. Virus Diseases1 (2022): 1-22.
16. Tian YY., et al. “mRNA vaccines: a novel weapon to control infection disease”. Frontiers in Microbiology 13 (2022): 1008694.
17. Lu DY and Lu TR. “Covid-19 vaccine development, emergency workflow”. EC Emergency Medicine and Critical Care9 (2021): 23-25.
18. Lu DY., et al. “HAART in HIV/AIDS treatments, future trends”. Infectious Disorders-Drug Targets1 (2018): 15-22.
19. Lu DY and Lu TR. “HIV/AIDS curability study, different approaches and drug combination”. Infectious Disorders-Drug Targets4 (2023): e170123212803.
20. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
21. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.
22. Crowe D. “SARS-steroid and ribavirin scandal”. The Infectious Myth (2020).
23. Ledford H. “How does COVID-19 kill? Uncertainty is hampering doctor’s ability to choose treatment”. Nature 7803 (2020): 311-312.
24. Kebede T., et al. “Potential drug option for treatment of COVID-19: A review”. Coronavirus1 (2020): 42-49.
25. Banday A., et al. “Potential immunotherapy against SARS-Cov-2, strategy and status”. Coronavirus1 (2020): 23-31.
26. Maxmen A. “How blood from coronavirus survivors might save lives”. Nature7801 (2020): 16-17.
27. Liu W., et al. “Effective chemicals against novel coronavirus (COVID-19) in China”. Current Topics in Medicinal Chemistry8 (2020): 603-605.
28. Blaising J., et al. “Arbidolas as a broad-spectrum antiviral: an update”. Antiviral Research 107 (2014): 84-94.
29. Silveira D., et al. “COVID-19: Is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?” Frontiers in Pharmacology 11 (2020): 581840.
30. Behi T., et al. “Phytochemicals from plant foods as potential source of antiviral agents: An overview”. Pharmaceuticals4 (2021): 381.
31. Mani JS., et al. “Natural product-derived phytochemicals as potential agents against coronaviruses, a review”. Virus Research 284 (2020): 197989.
32. Chojnacka K., et al. “Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus”. Journal of Functional Foods 73 (2020): 104146.
33. Mazzaedoost S., et al. “Covid-19 treatment plant compounds”. Advances in Applied Nano-Bio Technologies 1 (2020): 23-33.
34. Sytar O., et al. “COVID-19 prophylaxis efforts based on natural antiviral plant extracts and their compounds”. Molecules3 (2021): 727.
35. Lu DY., et al. “Discover natural chemical drugs in modern medicines”. Metabolomics3 (2016): 181.
36. Otekunrin OA., et al. “COVID-19 in Nigeria: Why continuous spike in cases?” Asian Pacific Journal of Tropical Medicine1 (2021): 1-4.
37. Pattanayak S. “Alternative to antibiotics from herbal origin—outline of a comprehensive research project”. Current Pharmacogenomics Personalized Medicine1 (2018): 9-62.
38. Wang YX., et al. “Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19”. European Review for Medical and Pharmacological Sciences 6 (2020): 3360-3384.
39. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice and Palliative Medicine International Journal 4 (2019): 125-130.
40. Silveira D., et al. “COVID-19: Is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?” Frontiers in Pharmacology 11 (2020): 581840.
41. Carvalho APA and Conte-Junior CA. “Recent advances on nanomaterials to COVID-19 management; A systematic review on antiviral/virucidal agents and mechanisms of SARS-CoV-2 inhibition/inactivation”. Global Challenge5 (2021): 2000115.
42. Raghav N., et al. “Nanocellulose: A mini-review on types and use in drug delivery systems”. Carbohydrate Polymer Technologies and Applications 2 (2021): 100031.
43. Sberna G., et al. “In vitro evaluation of antiviral efficacy of a standardized hydroalcoholic extract of poplar type propolis against SARS-CoV-2”. Frontiers in Microbiology 13 (2022): 799546.
44. Ripari N., et al. “Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment”. Journal of Pharmacy and Pharmacology 3 (2021): 281-299.
45. Lu DY and Lu TR. “Covid-19 study, diagnostic and therapeutic transition”. Recent Advances in Anti-Infective Drug Discovery 1 (2024): 21-35.
46. Lu DY and Lu TR. “COVID-19 study: a new principle discovery”. Current Drug Therapy 20 (2025).
47. Freedman DH. “Hunting for new drugs with AI”. Nature 7787 (2019): s49-s53.
48. Pariak C., et al. “Can the antivirals remdesivir and favipiravir work jointly? In silico insights”. Drug Research 1 (2022): 34-40.
49. Viana JDO., et al. “Drug discovery and computational strategies in the multitarget drugs era”. Brazilian Journal of Pharmaceutical Sciences 54 (2018): e01010.
50. Scotti L., et al. “In-silico analyses of natural products on Leishmania enzyme targets”. Mini-Reviews in Medicinal Chemistry 3 (2015): 253-269.
51. Yadav M and Eswari JS. “Modern paradigms towards potential target identification for antiviral (SARS-nCoV-2) and anticancer lipopeptides: a pharmacophore-based approach”. Avicenna Journal of Medical Biotechnology 1 (2022): 70-78.
52. Kalirajan R. “Activity of some novel chalcone-substituted 9-anilinoacridines against coronavirus (COVID-19): A computational approach”. Coronavirus1 (2020): 13-22.
53. Qamar T., et al. “SARS-CoV-2-induced phosphorylation and its pharmacotherapy backed by artificial intelligence and machine learning”. Future Science OA 1 (2024): FSO917.
54. Islam R., et al. “In silico prediction of common siRNA targets protein coding sequence of NS5 gene of west Nile and Japanese encephalitis virus”. Trends in Peptide and Protein Science 8 (2023): e6.
55. Vogele J., et al. “High resolution structure of stem-loop4 from the 5’-UTR of SARS-CoV-2 solved by solution state NMR”. Nucleic Acids Research 20 (2023): 11318-11331.
56. Jin X., et al. “Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-Co-V-2 evolution potentially related to furin cleavage site”. Emerging Microbes and Infection1 (2020): 1474-1488.
57. Bhatia R., et al. “Repurposing of RdRp inhibitors against SARS-Cov-2 through molecular docking tools”. Coronavirus1 (2020): 108-116.
58. Huang DC., et al. “Al-driven drug discovery: accelerating the development of novel therapeutics in biopharmaceuticals”. International Medical Science Research Journal 8 (2024): 882-899.
59. Shinde PS., et al. “The role of artificial intelligence in the pharmaceutical sector: a comprehensive analysis of its application from the discovery phase to industrial implementation”. International Journal of Drug Delivery Technology 4 (2023): 1578-1584.
60. Dashpute SV., et al. “Artificial intelligence and machine learning in the pharmaceutical industry”. International Journal of Pharmacy and Pharmaceutical Sciences 2 (2023): 111-131.
61. Ferreira LLG and Andricopulo AD. “COVID-19: small-molecule clinical trial landscape”. Current Topics in Medicinal Chemistry18 (2020): 1577-1580.
62. Kneller DW., et al. “Direct observation of protonation state modulation in SARS-CoV-2 main protease upon inhibitor binding with neutron crystallography”. Journal of Medicinal Chemistry 8 (2021): 4991-5000.
63. Zhao Y., et al. “High-throughput screening identifies established drugs as SARS-CoV-2 PL pro inhibitors”. Protein Cell 11 (2021): 877-888.
64. Bhatia R., et al. “Repurposing of RdRp inhibitors against SARS-Cov-2 through molecular docking tools”. Coronavirus1 (2020): 108-116.
65. Atnaf A., et al. “Hematological profiles and clinical outcome of COVID-19 among patient’s admitted at Debre Markos isolation and treatment center: 2020L a prospective cohort study”. Journal of Blood Medicine 13 (2022): 631-641.
66. Mpiana PT., et al. “Aloe vera (L.) Burm F as a potential of anti-COVID-19 plant: A mini-review of its antiviral activity”. European Journal of Medicinal Plants 8 (2020): 86-93.
67. Ghoran SH., et al. “Natural products from medicinal plants with anti-human coronavirus activities”. Molecules 6 (2021): 1754.
68. Akram M., et al. “Ethnopharmacological properties of Asian medicinal plants during conflict-related blockades”. Phytochemistry, the Military and Health (Elsevier) Chapter 5 (2021): 53-68.
69. Clever S and Volz A. “Mouse models in COVID-19 research: analyzing the adaptive immune response”. Medical Microbiology and Immunology 2 (2022): 165-183.
70. Brenbdler T., et al. “Botanical drugs and supplements affecting the immune response in the time of COVID-19: implication for research and clinical practice”. Phytotherapy Research 6 (2020): 3013-3031.
71. Inkoto CL., et al. “A mini review on the phytochemistry and pharmacology of Aframomum alboviolaceum (zingiberaceae)”. South Asian Research Journal of Natural Products 3 (2021): 24-35.
72. de Wilde AH., et al. “Host factors in coronavirus replication”. Current Topics in Microbiology and Immunology 419 (2018): 1-42.
73. Lu DY., et al. “Avian flu, pathogenesis and therapy”. Anti-Infective Agents2 (2012): 124-129.
74. Lu DY., et al. “Ebola therapeutic study and future trends”. Infectious Disorders - Drug Targets 1 (2019): 17-29.
75. Rao DV., et al. “Translational approach in emerging infectious disease treatment: an update”. Biomedical Research12 (2017): 5678-5686.
76. Randolph HE and Barreiro LB. “Herd immunity: understanding COVID-19”. Immunity5 (2020): 737-741.
77. Lu DY and Ding J. “Sequencing the whole genome of infected human cells obtained from diseased patients—a proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases”. Medical Hypotheses 68 (2007): 826-827.
78. Lu DY and Ding J. “AIDS and human genome studies, from a hypothesis to systematic approaches”. Medical Hypotheses 3 (2007): 695.
79. Downes DJ., et al. “Identification of LZTTL11 as a candidate effector gene at a COVID-19 risk locus”. Nature Genetics 11 (2021): 1606-1615.
80. Lander ES. “Initial impact of the sequencing of the human genome”. Nature7333 (2011): 187-197.
81. Maher B. “Genomes on prescriptions”. Nature7367 (2011): 22-24.
82. Dabin K. “Our mutual friends: cancer research in a time of COVID-19”. Interface Focus 121 (2021): 20210052.
83. Scholey J., et al. “Life expectancy changes since COVID-19”. Nature Human Behaviour 12 (2022): 1649-1659.
84. He ZM., et al. “Recent advances towards natural plants as potential inhibitors of SARS-CoV-2 targets”. Pharmaceutical Biology1 (2023): 1186-1210.
85. Moschovou K., et al. “Exploring the binding effects of natural products and anti-hypertensive drugs on SARS-Co-2: An in silico investigation of main protease and spike proteins”. International Journal of Medical Sciences 21 (2023): 15894.
86. Duval D., et al. “Critical appraisal in rapid systematic reviews of COVID-19 studies: implementation of the quality criteria checklist (QCC)”. Systematic Review 12 (2023): 55.